Ranbaxy Laboratories Ltd. has signed a new, multiyear R&D agreement with GlaxoSmithKline, expanding the terms of their strategic alliance established in 2003. The expanded alliance includes GSK’s therapeutics of interest, such as anti-infectives, metabolic, respiratory and oncology products. Under the original agreement, Ranbaxy conducted the optimization chemistry for progressing drug leads to the stage of candidate selection. Under the new agreement, Ranbaxy will advance leads...